

Cerebral Venous Thrombosis in Tropical Areas

Dr Chandrashekhar Meshram

Director, Brain and Mind Institute,

Nagpur, India

drmeshram@hotmail.com

Disclosures

None

Due to copyright reasons, more images will be included in the final presentation.

Learning Objectives

- Risk Factors of CVT
- Clinical Manifestations of CVT
- Diagnosis of CVT
- Treatment of CVT

Why CVT is important

- Heterogeneous condition
- Varied clinical manifestation
- Change in pattern
- Different predisposing factors
- Good prognosis

CVT – Age and Sex

| Country | Author | Year | N= | M % | F % | Mean Age |
|-----------------|------------|------|-------|-----|-----|----------|
| Brazil | Christo P | 2010 | 15 | 27 | 73 | 36 |
| Chile | Truzillo O | 2016 | 62 | 13 | 87 | 37 |
| Morocco | Souirti Z | 2014 | 30 | 30 | 70 | 29 |
| Saudi Arabia | Rizwana S | 2019 | 26 | 42 | 58 | 29 |
| Turkey | Duman T | 2017 | 1144 | 32 | 68 | 38 |
| Tunisia | Sassi S | 2017 | 160 | 17 | 83 | 37 |
| Pakistan UAE | Khealani | 2008 | 109 | 47 | 53 | 35 |
| India | Narayan | 2012 | 428 | 54 | 46 | 31 |
| India | Pai | 2013 | 573 | 62 | 38 | 34 |
| India | Meshram | 2019 | 894 | 68 | 32 | 32 |
| ISCVT-21C | Ferro J | 2004 | 624 | 26 | 74 | 39 |
| 112 Studies | Zuurbier | 2016 | 23638 | 35 | 65 | 37 |

Cerebral Venous Thrombosis

Risk Factors (Genetic)

- **Deficiency of anticoagulants**
 - Antithrombin III
 - Protein C , Protein S
- **Abnormal Proteins**
 - Factor V Leiden
 - Dysfibrinogen
- **Increased Procoagulants**
 - Prothrombin , Factor VIII
- **Abnormal Metabolism**
 - Homocysteinaemia

Cerebral Venous Thrombosis

Risk Factors – Acquired

Tissue trauma – surgery

Pregnancy & Puerperium

Malignancy

Sepsis

Nephrotic syndrome

Hyperviscosity state, Dehydration

APLA , PNH

Myeloproliferatus disorders

Hyperhomocysteinaemia

Oral Contraceptive

Inflammatory diseases- Crohns, Behcets, ulc colitis

Drug Abuse,Alcohol

Balance between
Procoagulants & anticoagulants
keeps the blood fluid & flowing.

Increased Procoagulants &/or
decreased anticoagulants can
lead to thrombosis.

Why CVT common in Tropical areas

- Anemia
- B12 Deficiency
- Hyperhomocysteinaemia
- Poor obstetrics care
- Dehydration
- Raised Hematocrit
- Infection
- Genetic
- Other environmental factors



Clinical Presentations

four main syndromes

- Raised intracranial Pressure
- Presentation with Seizures
- Stroke like Presentation with Focal Deficit
- Encephalopathy


GR 17 M

- Headache 3 wks
- Vomiting
- Papilloedema



DT 42 M

- Swelling Lt side of neck
- Headache
- Diplopia – VI nerve palsy
- Papilledema




VK 36 m

- Headache – 5 days
- Seizures
- No focal deficit


NM 26 M

- Headache – 7 days
- Seizures – 4 days
- Rt. Hemiparesis – 1 day



PU 40 M




- Headache
- Seizures
- Rt. Hemiparesis
- Altered Sensorium



Uncommon Presentation




- Subarachnoid Hemorrhage
- Cavernous Sinus Thrombosis
- Multiple cranial nerve palsies
- Deep venous Thrombosis
- Psychological Symptoms
- Recurrent Syncope
- Hearing Impairment

- SJ 35 F
- Headache
- Altered Sensorium



M B 56 M

- Loss of memory and irrelevant Talk
- Wernicke Aphasia
- DM, HT



CVT Suspect if

- Young Patient
- First time headache
- Occipital Headache U/ L → B/L
- Neck Pain
- Headache - seizures
- Papilledema
- H/o Blackouts , Diplopia
- Insidious onset with indolent course
- Altered sensorium

Diagnosis

CVT- Neuroimaging Studies

MRI with MRV

| Duration | T1 | T2 |
|---------------|--------------|--------------|
| Upto 5 days | Isointense | Hypointense |
| 6- 9 days | Hyperintense | Isointense |
| 10-15 days | Hyperintense | Hyperintense |
| After 15 days | Hypointense | Hypointense |

- Parenchymal Changes
- MRI using gradient T2* Susceptibility weighted sequences
- MRV – TOF –Time of flight technique
- Contrast enhanced MRV

CVT – Neuroimaging Study

CT Scan

- Dense Triangle Sign
- Cord Sign
- Parenchymal Abnormality
- CECT – Empty Delta Sign
- CT Venography

Lab Tests- D Dimer

- Meta-analysis of 14 studies
- Sensitivity – 93.9 %
- Sensitivity - 89.7 %
- Normal D Dimer does not exclude presence of CVT

CVT - Investigations

1. Hereditary Abnormalities
 - Activated Protein C Resistance
(Factor V Leiden)
 - Antithrombin Functional Assay
 - Protein C functional assay
 - Protein S Functional Assay
 - Fibrinogen
2. Aquired Abnormalities
 - APLA
 - Fasting Plasma Homocystein Level

CVT – When to do tests for Thrombophilic factors

- During Stable State
- Not During Acute Thrombosis
- Not When on Anticoagulants

CVT - Treatment

- Symptomatic
- Treatment of Underlying cause
- Treatment of thrombotic Process

Treatment

- Anticoagulation Aim
 - to recanalise occluded Sinus
 - Prevent Propagation of Thrombus
 - Treat underlying Prothrombotic state

CVT- Treatment Anticoagulants

- Heparin
I.V. unfractionated heparin
Bolus 80u/kg followed by
18u/kg/hr
- LMW Heparin




Chronic CVT- Dural AVM

CVT Treatment

- Oral anticoagulants
- How long to continue


DJ 42 M

- Lt. Hemiplegia, Seizures
- Lupus anticoagulant +ve



IG 39 M

- CVT-On oral Anticoagulants for 2 years
- Asymptomatic
- Anticoagulants stopped
- After 2 weeks



Genetic Thrombophilia

- Lifelong anticoagulants

Evidence based medicine to
experience based medicine

CVT – Treatment

Endovascular Thrombolysis



- Urokinase
- rtPA

CVT – Treatment

- Mechanical Thrombolysis

CVT – Treatment

- Decompressive Craniotomy
- Life saving measure in case of large venous infarction .



CVT – Prognosis

- Mortality
- Functional recovery is much better as compared to arterial stroke.

CVT – Key Message

- Key to diagnosis is – High index of suspicion.
- Disease of the young
- MRI with MRV is investigation of choice
- Investigate for predisposing conditions
- Early diagnosis would lead to early start of treatment and better prognosis
- Anticoagulation is the treatment of choice even in the patients with hemorrhagic lesions

CVT – References

- Narayan D, Kaul S, Ravishankar K, Suryaprabha T, Bandaru VC, Mridula KR, *et al*. Risk factors, clinical profile, and long-term outcome of 428 patients of cerebral sinus venous thrombosis: Insights from Nizam's Institute Venous Stroke Registry Hyderabad (India). *Neurol India* 2012;60 : 154-9
- Pai N, Ghosh K, Shetty S. Hereditary thrombophilia in cerebral venous thrombosis: A study from India. *Blood Coagul Fibrinolysis* 2013;24:540-3
- Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F, ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: Results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). *Stroke* 2004;35:664-70.
- Khealani BA, Wasay M, Saadah M, Sultana E, Mustafa S, Khan FS, *et al*. Cerebral venous thrombosis: A descriptive multicenter study of patients in Pakistan and Middle East. *Stroke* 2008;39:2707-11
- Canhão P, Falcão F, Ferro JM. Thrombolytics for cerebral sinus thrombosis: A systematic review. *Cerebrovasc Dis* 2003;15:159-66.
- J. M. Ferro^{a,b}, M.-G. Bousser^c, P. Canhão^{a,b}, J. M. Coutinho^d, I. Crassard^c, F. Dentalie^e, M. di Minno^{f,g}, A. Mainoh^h, I. Martinelli^h, F. Masuhriⁱ, D. Aguiar de Sousa^a and J. Stam^d, for the European Stroke Organization, European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis – endorsed by the European Academy of Neurology, *European Journal of Neurology* 2017, 0: 1–11
- Luo Y, Tian X and Wang X (2018) Diagnosis and Treatment of Cerebral Venous Thrombosis: A Review. *Front. Aging Neurosci.* 10:2. doi: 10.3389/fnagi.2018.00002
- Samia Ben Sassi, , Nahla Touati, , Hela Baccouche, , Cyrine Drissi, , Neila Ben Romdhane, , and Fayçal Hentati, Cerebral Venous Thrombosis: A Tunisian Monocenter Study on 160 Patients *Clinical and Applied Thrombosis/Hemostasis* 2017, Vol. 23(8) 1005-1009
- Zurbier, S. M. (2016). Cerebral venous thrombosis: Epidemiology, clinical course, and outcome.
- Cao V, Agnelli G, Paciaroni M *Handbook of Cerebral Venous Thrombosis* Karger 2008
- Dash D, Prasad K, Joseph L. Cerebral venous thrombosis: An Indian perspective. *Neurol India* 2015;63:318-28
- Dentali F, Squizzato A, Marchesi C, Bonzini M, Ferro JM, Ageno W. D-dimer testing in the diagnosis of cerebral vein thrombosis: A systematic review and a meta-analysis of the literature. *J Thromb Haemost* 2012;10:582-9
- Seon-Kyu Lee, Maxim Mokin, Steven W Hetts, Johanna T Fifi, Marie-Germaine Bousser, Justin F Fraser, Current endovascular strategies for cerebral venous thrombosis: report of the SNIS Standards and Guidelines Committee *J NeuroIntervent Surg* 2018;10:803–810.
-